Key Highlights
- Rondo Therapeutics appoints Steven James to its Board of Directors.
- Mr. James brings over three decades of biopharmaceutical experience.
- Strengthens Rondo’s focus on T-cell engaging bispecific antibodies for solid tumors.
- Previous roles include CEO of Pionyr Immunotherapeutics, Labrys Biologics, and KAI Pharmaceuticals.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome Steve to the Board. With Steve’s business acumen and transactional experience, our board and leadership team are uniquely positioned to deliver transformative solid tumor therapies to patients.” — Shelley Force Aldred, Co-founder and CEO at Rondo Therapeutics
- “There is great therapeutic potential for bispecific antibodies to address significant unmet needs in solid tumors. I am impressed by what the team at Rondo Therapeutics has accomplished to date, and I am excited to be a part of Rondo’s continued growth.” — Steven James, Board of Directors at Rondo Therapeutics
SoHC's Take
The addition of Steven James to the Rondo Therapeutics Board of Directors represents a strategic move to strengthen the company’s leadership team with seasoned expertise. With a proven track record in leading biopharmaceutical companies to success and significant M&A achievements, Mr. James’ involvement is expected to accelerate Rondo’s mission to develop innovative bispecific antibody therapies for solid tumors. This appointment underscores Rondo’s commitment to advancing cancer therapies and positions the company for continued growth and breakthrough advancements in the field.
